Global Pharmacogenetic Testing Market Size, Trends, and Growth Opportunity, By Type (Single Gene Tests, Array-Based Tests, Whole Genome Sequencing, NGS, Whole Exome Sequencing), By Sample (Blood and Saliva), By Therapeutic Area (Oncology, Neurology, Cardiology, Genomics, Immunology and Hypersensitivity, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies, and Direct-To-Customer Services), By Region and Forecast to 2030. 
Global Pharmacogenetic Testing Market 
The Global Pharmacogenetic Testing Market was valued at USD 6.25 billion in 2022 and is expected to expand to USD 13.5 billion by 2030, at a CAGR of 9.05% during the forecast period 2023-2030.
Pharmacogenetic testing provides data about individuals' genes to help their healthcare provider choose the medicine and dosage that are the best fit for them. The tests use a sample of saliva, blood, and cells swabbed from individuals’ cheeks. Pharmacogenetic testing is also referred to as precision medicine.
Market Drivers
The rising popularity of precision medicine particularly enhances the pharmacogenomics market. Also, increasing R&D expenditure on pharmacogenomics technologies is determining to the fast development of novel products. The high prevalence rate of adverse drug reactions is also leading to the rising adoption of pharmacogenomics in the global market.  
Furthermore, the growing elderly population boosts the global pharmacogenetic testing market. Elderly people are more vulnerable to treatment failures and many adverse drug reactions. Pharmacogenomics allows the screening of adverse drug reactions related to personalized medicine regimes. Thus, this factor boosts the market growth.
Market Restraints
Pharmacogenomic testing solutions do not provide information about biomarkers, thus, they cannot guide physicians properly in determining diseases to improve symptoms. These tests are only for some of the most common genetic disorders, so rare alleles will not be detected. This factor is hindering the global pharmacogenetic testing market growth.
Market Segmentation
The global pharmacogenetic testing market is segmented into type, sample, therapeutic area, distribution channel, and region.
Based on type, the global pharmacogenetic testing market is segmented into single gene tests, array-based tests, whole genome sequencing, NGS, and whole exome sequencing.
Based on the sample, the global pharmacogenetic testing market is segmented into blood and saliva.
Further, based on therapeutic area, the market is segmented into oncology, neurology, cardiology, and genomics.
Regional Analysis
The global pharmacogenetic testing market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The North American region is expected to dominate the pharmacogenetic testing market owing to the well-developed healthcare sector. Also, the incidence of advanced pharmacogenetic testing methods shall further increase the growth of the market in the region during the forecast period of 2030.
The Asia-Pacific region is expected to witness a significant growth rate due to the incidence of a vast patient population and a surge in the geriatric population. 
Key Players
Various key players are discussed in the global pharmacogenetic testing market report including; Abbott Laboratories, Dynamic DNA Laboratories, Empire Genomics, LLC, F. Hoffmann-La Roche Ltd., Illumina, Inc., OneOme LLC, Myriad Genetics Inc., OPKO Health, Inc. (GeneDx), and Thermo Fisher Scientific, Inc., Assurex Health Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG.
For instance, in 2022, Invitae launched the extended ‘Invitae Pharmacogenomics Panel’, which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool.
Market Taxonomy
By Type
•        Single Gene Tests
•        Array-Based Tests
•        Whole Genome Sequencing
•        NGS
•        Whole Exome Sequencing
By Sample
•        Blood
•        Saliva
By Therapeutic Area
•        Oncology
•        Neurology
•        Cardiology
•        Genomics
•        Immunology
•        Hypersensitivity
•        Others
By Distribution Channel
•        Hospital Pharmacies
•        Retail Pharmacies
•        Mail-Order Pharmacies
•        Direct-To-Customer Services
By Region
•        North America
•        Latin America
•        Europe
•        Asia Pacific
•        Middle East & Africa

Global Pharmacogenetic Testing Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Pharmacogenetic Testing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact Due To Recent Energy Crisis
4.2.5 Cumulative Impact Due Nearing Economic Downturn
4.2.6 Post-Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact Of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Pharmacogenetic Testing Market, By Type
5.1 Y-o-Y Growth Comparison, By Type
5.2 Global Pharmacogenetic Testing Market Share Analysis, By Type
5.3 Global Pharmacogenetic Testing Market Size and Forecast, By Type
5.3.1 Single Gene Tests
5.3.2 Array-Based Tests
5.3.3 Whole Genome Sequencing
5.3.4 NGS
5.3.5 Whole Exome Sequencing
6 Global Pharmacogenetic Testing Market, By Sample
6.1 Y-o-Y Growth Comparison, By Sample
6.2 Global Pharmacogenetic Testing Market Share Analysis, By Sample
6.3 Global Pharmacogenetic Testing Market Size and Forecast, By Sample
6.3.1 Blood
6.3.2 Saliva
7 Global Pharmacogenetic Testing Market, By Therapeutic Area
7.1 Y-o-Y Growth Comparison, By Therapeutic Area
7.2 Global Pharmacogenetic Testing Market Share Analysis, By Therapeutic Area
7.3 Global Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
7.3.1 Oncology
7.3.2 Neurology
7.3.3 Cardiology
7.3.4 Genomics
7.3.5 Immunology
7.3.6 Hypersensitivity
7.3.7 Others
8 Global Pharmacogenetic Testing Market, By Distribution Channel
8.1 Y-o-Y Growth Comparison, By Distribution Channel
8.2 Global Pharmacogenetic Testing Market Share Analysis, By Distribution Channel
8.3 Global Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
8.3.1 Hospital Pharmacies
8.3.2 Retail Pharmacies
8.3.3 Mail-Order Pharmacies
8.3.4 Direct-To-Customer Services
9 Global Pharmacogenetic Testing Market, By Region
9.1 Global Pharmacogenetic Testing Market Share Analysis, By Region
9.2 Global Pharmacogenetic Testing Market Share Analysis, By Region
9.3 Global Pharmacogenetic Testing Market Size and Forecast, By Region
10 North America Pharmacogenetic Testing Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 North America Pharmacogenetic Testing Market Share Analysis, By Type
10.3 North America Pharmacogenetic Testing Market Size and Forecast, By Sample
10.4 North America Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
10.5 North America Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
10.6 North America Pharmacogenetic Testing Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11 Europe Pharmacogenetic Testing Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Europe Pharmacogenetic Testing Market Share Analysis, By Type
11.3 Europe Pharmacogenetic Testing Market Size and Forecast, By Sample
11.4 Europe Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
11.5 Europe Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
11.5 Europe Pharmacogenetic Testing Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.6.4 Rest of Europe
12 Asia Pacific Pharmacogenetic Testing Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Asia Pacific Pharmacogenetic Testing Market Share Analysis, By Type
12.3 Asia Pacific Pharmacogenetic Testing Market Size and Forecast, By Sample
12.4 Asia Pacific Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
12.5 Asia Pacific Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
12.6 Asia Pacific Pharmacogenetic Testing Market Size and Forecast, By Country
12.6.1 China        
12.6.2 Japan
12.6.3 India
12.6.4 Rest of Asia Pacific
13 Latin America Pharmacogenetic Testing Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America Pharmacogenetic Testing Market Share Analysis, By Type
13.3 Latin America Pharmacogenetic Testing Market Size and Forecast, By Sample
13.4 Latin America Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
13.5 Latin America Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
13.6 Latin America Pharmacogenetic Testing Market Size and Forecast, Country
13.6.1 Brazil
13.6.2 Rest of Latin America
14 Middle East Pharmacogenetic Testing Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East Pharmacogenetic Testing Market Share Analysis, By Type
14.3 Middle East Pharmacogenetic Testing Market Size and Forecast, By Sample
14.4 Middle East Pharmacogenetic Testing Market Size and Forecast, By Therapeutic Area
14.5 Middle East Pharmacogenetic Testing Market Size and Forecast, By Distribution Channel
14.6 Middle East Pharmacogenetic Testing Market Size and Forecast, By Country
14.6.1 Saudi Arabia
14.6.2 UAE
14.6.3 Egypt
14.6.4 Kuwait
14.6.5 South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market Share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Abbott Laboratories
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Dynamic DNA Laboratories
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Empire Genomics LLC
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 F. Hoffmann-La Roche Ltd.
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Illumina, Inc.
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 OneOme LLC
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Myriad Genetics Inc.
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies        
16.8 OPKO Health, Inc. (GeneDx)
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Thermo Fisher Scientific, Inc.
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Assurex Health Inc.
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies